Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonucleic acid (RNA) is a fundamental biological macromolecule that plays a central role in the translation of genetic information into functional proteins. In proliferating cells, such as those found in malignant tumors, RNA metabolism is significantly accelerated to meet the high demand for protein synthesis required for rapid cell growth and division (Warner & McIntosh, 2009, Nature Reviews Molecular Cell Biology). This increased activity, particularly the synthesis of ribosomal RNA (rRNA) within the nucleolus, makes RNA a critical focal point for therapeutic intervention (Drygin et al., 2011, Cancer Research). Drugs targeting RNA typically function by inhibiting the enzymes responsible for its synthesis, such as RNA Polymerase I, or by acting as nucleotide analogs that incorporate into the RNA strand to cause structural and functional defects (Burger et al., 2010, Journal of Biological Chemistry). For example, the antimetabolite 5-fluorouracil is known to disrupt RNA processing and translation through its incorporation into various RNA species (Longley et al., 2003, Nature Reviews Cancer). Additionally, novel small molecules like CX-5461 specifically target the transcription of rRNA to induce cell cycle arrest and apoptosis in cancer cells (Drygin et al., 2011, Cancer Research). While targeting RNA is an effective strategy for inhibiting cell proliferation, it presents significant challenges, including the risk of systemic toxicity and the difficulty of achieving high selectivity for diseased versus healthy cells (Butzow & Eichhorn, 1975, Nature). Therapeutic monitoring often involves assessing RNA expression levels or nucleolar morphology as biomarkers of efficacy.
Inhibition of RNA synthesis (e.g., via RNA Polymerase I inhibition), incorporation of nucleotide analogs into RNA strands causing functional disruption, and targeted degradation of specific RNA species.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonucleic acid (RNA) (RNA).